Bicocca Open Archive

Logo unimib boa
CECCON, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.655
AS - Asia 2.034
EU - Europa 1.760
SA - Sud America 301
AF - Africa 64
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.529
SG - Singapore 748
CN - Cina 435
DE - Germania 344
IT - Italia 274
VN - Vietnam 264
HK - Hong Kong 242
RU - Federazione Russa 230
BR - Brasile 214
IE - Irlanda 193
SE - Svezia 191
GB - Regno Unito 130
CA - Canada 104
UA - Ucraina 96
FR - Francia 82
IN - India 75
FI - Finlandia 51
AT - Austria 42
BD - Bangladesh 35
AR - Argentina 33
TR - Turchia 32
PL - Polonia 31
IQ - Iraq 28
ID - Indonesia 27
JP - Giappone 26
KR - Corea 24
ZA - Sudafrica 24
BE - Belgio 21
ES - Italia 21
PK - Pakistan 19
DK - Danimarca 14
MA - Marocco 14
NL - Olanda 14
CO - Colombia 12
MX - Messico 12
SA - Arabia Saudita 12
VE - Venezuela 11
CL - Cile 8
UZ - Uzbekistan 8
EC - Ecuador 7
PH - Filippine 7
PY - Paraguay 7
JO - Giordania 6
KE - Kenya 6
LT - Lituania 6
TN - Tunisia 6
IR - Iran 5
NP - Nepal 5
PE - Perù 5
TH - Thailandia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
PS - Palestinian Territory 4
AU - Australia 3
BO - Bolivia 3
DZ - Algeria 3
KG - Kirghizistan 3
MY - Malesia 3
NG - Nigeria 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
HU - Ungheria 2
IL - Israele 2
KZ - Kazakistan 2
MU - Mauritius 2
PA - Panama 2
SI - Slovenia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 7.818
Salva come PNG Salva come JPEG
Città #
Ann Arbor 502
Singapore 402
Ashburn 320
Hong Kong 240
Frankfurt am Main 223
San Jose 212
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 190
Houston 157
Milan 144
Wilmington 137
Dearborn 107
New York 104
Jacksonville 90
Seattle 89
Los Angeles 83
Cambridge 74
Beijing 70
Ho Chi Minh City 70
Santa Clara 66
Hanoi 63
Princeton 53
Nanjing 47
Chicago 45
The Dalles 43
Dallas 42
Toronto 41
Vienna 36
Munich 29
Hefei 28
Lauterbourg 28
São Paulo 28
Shanghai 26
Altamura 24
Lawrence 23
Nanchang 22
Council Bluffs 21
Seoul 21
Brussels 19
Warsaw 19
Buffalo 18
Helsinki 18
Montreal 18
Moscow 18
Jakarta 17
San Diego 17
Tokyo 17
Da Nang 16
Orem 16
Boardman 15
Lachine 15
Turku 15
Brooklyn 14
Denver 13
Fremont 13
Guangzhou 13
Johannesburg 13
Rio de Janeiro 13
Göttingen 12
Chennai 11
London 11
Atlanta 10
Norwalk 10
Phoenix 10
Poplar 10
Baghdad 9
Falls Church 9
Haiphong 9
Hangzhou 9
Lahore 9
Lissone 9
Manchester 9
Pune 9
Salt Lake City 9
Andover 8
Ottawa 8
Shenyang 8
Tianjin 8
Amsterdam 7
Brasília 7
Chengdu 7
Edmonton 7
Jiaxing 7
Lodz 7
San Francisco 7
Stockholm 7
Taizhou 7
Tashkent 7
Amman 6
Boston 6
Düsseldorf 6
Hebei 6
Kunming 6
Nuremberg 6
Paris 6
Romola 6
Ankara 5
Changsha 5
Totale 5.151
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 522
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 440
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 418
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 397
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 367
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 350
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 327
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 324
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 310
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 307
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 283
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 280
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 278
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 268
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 266
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 252
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 249
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 240
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 232
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 219
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 214
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 210
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 201
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 200
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 193
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 189
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 183
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 172
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 146
Totale 8.037
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.475
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.475
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202191 0 0 0 0 0 0 0 0 0 0 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/20251.115 67 114 57 54 100 42 75 31 134 181 90 170
2025/20262.781 362 137 226 384 386 150 426 118 263 262 67 0
Totale 8.037